Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 1.02B 894M 823M 770M 1.44B 95.98B 1.47B 9.88B 3.83B 47.32B 3.82B 3.74B 164B P/E 2026 *
-14.5x
P/E 2027 * -12.1x
Enterprise Value 1.02B 894M 823M 770M 1.44B 95.98B 1.47B 9.88B 3.83B 47.32B 3.82B 3.74B 164B EV / Sales 2026 *
26.7x
EV / Sales 2027 * 50.5x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
1 day+5.90%
1 week+12.04%
Current month+10.50%
1 month+16.93%
3 months+47.78%
6 months+95.84%
Current year+109.46%
1 week 1.98
Extreme 1.985
2.51
1 month 1.8
Extreme 1.8
2.51
Current year 1.1
Extreme 1.1
2.53
1 year 0.8
Extreme 0.8006
2.53
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 2024-07-07
Director of Finance/CFO 59 2025-01-01
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 83 2004-12-31
Chairman 71 2012-02-26
Director/Board Member 67 2007-08-27
Date Insider Type Main position Quantity % Market Cap.
06-02Fiscal year

Director

178,624 0.0402%
06-02Fiscal year

Director

178,624 0.0402%
06-02
The Invus Group LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+5.90%+12.04%+159.21%+11.00% 1.02B
+0.82%+1.94%+64.95%+120.34% 55.35B
+1.58%+14.12%+72.87%+85.18% 51.92B
+0.14%+0.16%-14.90%-15.52% 22.76B
+2.57%+9.01%+5.65%+439.88% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.28%+3.64%+28.24%-34.74% 16.1B
+3.02%+12.74%+143.33%+308.04% 13.96B
+2.74%+6.70%+27.15%+181.55% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +1.68%+6.63%+54.23%+120.36% 22.68B
Weighted average by Cap. +1.20%+6.58%+48.41%+124.28%

Financials

2026 *2027 *
Net sales 38.17M 33.53M 30.89M 28.88M 54.17M 3.6B 55.16M 371M 144M 1.78B 143M 140M 6.17B 20.15M 17.7M 16.31M 15.25M 28.6M 1.9B 29.13M 196M 75.8M 937M 75.68M 74.02M 3.26B
Net income -66.94M -58.8M -54.17M -50.65M -95M -6.32B -96.74M -650M -252M -3.11B -251M -246M -10.82B -88.26M -77.53M -71.43M -66.79M -125M -8.33B -128M -857M -332M -4.11B -331M -324M -14.27B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
26-06-26 US$2.410 +5.24% 1,846,427
26-06-25 US$2.290 +3.15% 3,395,327
26-06-24 US$2.220 +2.78% 2,823,421
26-06-23 US$2.160 +0.47% 2,774,239
26-06-22 US$2.150 +6.97% 3,035,727
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.290USD
Average target price
3.770USD
Spread / Average Target
+64.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock